Review
Biochemistry & Molecular Biology
Farzana Hossain, Shruthi Kandalai, Xiaozhuang Zhou, Nan Zhang, Qingfei Zheng
Summary: In this review, synthetic approaches for antigen-based cancer vaccines are highlighted, along with the discussion of various bioconjugation strategies. The progress of genetically modified cancer vaccines in clinical research is also summarized. Additionally, the synthesis of adjuvants and utilization of biomaterial scaffolds for enhancing immune responses are mentioned.
Article
Chemistry, Multidisciplinary
Xuedan He, Shiqi Zhou, Wei-Chiao Huang, Amal Seffouh, Moustafa T. Mabrouk, M. Thomas Morgan, Joaquin Ortega, Scott Abrams, Jonathan F. Lovell
Summary: A new vaccine adjuvant system was developed to induce strong cellular immune responses against multiple tumor cell lines, demonstrating durable immunity. The system showed the importance of stable particle formation for effective immune response induction and could control local and metastatic disease in a therapeutic setting.
Article
Immunology
Li Ou, Krishana Gulla, Andrea Biju, Daniel W. Biner, Tatsiana Bylund, Anita Changela, Steven J. Chen, Cheng-Yan Zheng, Nicole Cibelli, Angela R. Corrigan, Hongying Duan, Christopher A. Gonelli, Wing-Pui Kong, Cheng Cheng, Sijy O'Dell, Edward K. Sarfo, Andrew Shaddeau, Shuishu Wang, Alison Vinitsky, Yanhong Yang, Baoshan Zhang, Yaqiu Zhang, Richard A. Koup, Nicole A. Doria-Rose, Jason G. Gall, John R. Mascola, Peter D. Kwong
Summary: This study investigated the impact of varying linkers between FP8 and rTTHC in conjugate-vaccine immunogens. The results showed that linker length, hydrophilicity, and peptide-carrier stoichiometry had an effect on the immunogenicity of the conjugates, while several commonly used crosslinkers yielded similar serological results.
Article
Biochemistry & Molecular Biology
Stefania Cuzzubbo, Benoit Roch, Guillaume Darrasse-Jeze, Benoit Hosten, Manon Leclercq, Nicolas Vignal, Claire Banissi, Eric Tartour, Antoine F. Carpentier
Summary: This study found that a novel peptide vaccine platform based on synthetic melanin nanoaggregates can trigger strong immune responses and suppress tumor growth. Dendritic cells, especially migratory conventional type 1 dendritic cells, play a crucial role in the immune response after melanin-based vaccination. The research also demonstrated that L-DOPA melanin acts as an efficient carrier for peptides, protecting them from enzymatic degradation, and melanin-peptide nanoaggregates can persist in lymphoid tissues, explaining the sustained immune response observed with this vaccine technology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Samantha J. Paston, Victoria A. Brentville, Peter Symonds, Lindy G. Durrant
Summary: Vaccination has had a significant impact in preventing infectious diseases, but the development of therapeutic cancer vaccines has been challenging.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Hyeri Park, Mingliang Lin, Jian Zhou, Lisa M. Eubanks, Bin Zhou, Kim D. Janda
Summary: Opioid use disorders and overdose have become a major public health concern. U-47700, a new psychoactive substances opioid, is identified as a new threat in the drug supply due to its potency and abuse potential. The development of a U-47700 vaccine has shown promising results in rodents, generating antibodies that effectively mitigate drug-induced effects and prevent the drug from entering the brain.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Katarzyna Piadel, Amin Haybatollahi, Angus George Dalgleish, Peter Lawrence Smith
Summary: The study investigates alternative vaccine strategies to broaden T-cell responses and provide cross-immunity against SARS-CoV-2 variants and future coronavirus outbreaks. Highly conserved peptides containing immunogenic epitopes were synthesized and demonstrated antigenicity against T-cells from individuals with previous SARS-CoV-2 infection.
JOURNAL OF GENERAL VIROLOGY
(2022)
Review
Pharmacology & Pharmacy
Jing-Xing Yang, Jen-Chih Tseng, Guann-Yi Yu, Yunping Luo, Chi-Ying F. Huang, Yi-Ren Hong, Tsung-Hsien Chuang
Summary: Vaccines are important for controlling microbial infections and preventing epidemic diseases. The development of adjuvants, specifically Toll-like receptor (TLR) agonists, has seen significant progress in recent years for human vaccines. The COVID-19 pandemic has also accelerated the clinical research of TLR agonist-based adjuvants. This paper reviews the agonists for TLR activation and their molecular mechanisms, with a focus on recent advances in TLR agonist-based vaccine adjuvants for infectious diseases.
Review
Immunology
Samik Chakraborty, Juan Ye, Herui Wang, Mitchell Sun, Yaping Zhang, Xueyu Sang, Zhengping Zhuang
Summary: This review discusses the application and challenges of using Toll-like receptor (TLR) agonists as immunoadjuvants in cancer immunotherapy. Several studies have demonstrated the efficacy of TLR agonists as immunotherapy strategies, including monotherapy and combination therapy. The use of TLR agonists as adjuvants for cancer vaccines is a current focus of research.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Ruohan Wei, Xuemei Yang, Han Liu, Tongyao Wei, Sheng Chen, Xuechen Li
Summary: The study demonstrates that chemically synthesized Pse-CRM197 conjugates can stimulate high immune responses and provide a new alternative for controlling infections caused by multidrug-resistant A. baumannii.
ACS CENTRAL SCIENCE
(2021)
Article
Biochemistry & Molecular Biology
Chanju Lee, Soyoung Kim, Chanmi Jeong, Inhee Cho, Juyeon Jo, Ik-Hwan Han, Hyunsu Bae
Summary: The study suggests that targeting M2-like tumor-associated macrophages (TAMs) could be a potential therapeutic strategy for inhibiting breast cancer metastasis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Farrhana Z. Z. Firdaus, Stacey Bartlett, Waleed M. M. Hussein, Lantian Lu, Quentin Wright, Wenbin Huang, Ummey J. J. Nahar, Jieru Yang, Mattaka Khongkow, Margaret Veitch, Prashamsa Koirala, Uracha R. R. Ruktanonchai, Michael J. J. Monteiro, Jazmina L. Gonzalez L. Cruz, Rachel J. J. Stephenson, James W. W. Wells, Istvan Toth, Mariusz Skwarczynski
Summary: Human papilloma virus (HPV) is responsible for all cases of cervical cancer. Peptide-based vaccines, such as 8Qm conjugated to polyleucine, show promise as a therapeutic option with fewer side effects compared to chemotherapy and surgery. Liposomes incorporating the 8Qm conjugate demonstrated efficacy in tumor eradication, while the introduction of DC-targeting moieties did not significantly improve vaccine efficacy.
Article
Chemistry, Multidisciplinary
Ying Cai, Binyu Zhu, Xiaoting Shan, Lingli Zhou, Xujie Sun, Anqi Xia, Binhao Wu, Yang Yu, Helen He Zhu, Pengcheng Zhang, Yaping Li
Summary: This study demonstrates the potential of peptide-drug conjugate (PDC) filaments targeting TNBC cells and TECs to induce immunogenic cell death in tumor cells and downregulate Fas ligand expression in TECs, thereby increasing antitumor immunity and inhibiting tumor growth and metastasis. The synergistic modulation of cancer cells and TECs using this strategy shows promise for TNBC chemoimmunotherapy.
ADVANCED MATERIALS
(2023)
Review
Biochemistry & Molecular Biology
Arshpreet Kaur, Jeremy Baldwin, Deshkanwar Brar, Deepak B. Salunke, Nikolai Petrovsky
Summary: The development of new human adjuvants has been revolutionized by the discovery of toll-like receptors (TLRs), leading to a better understanding of their mechanisms of action. This work has important implications for the development of vaccines and immunotherapies against various diseases.
CURRENT OPINION IN CHEMICAL BIOLOGY
(2022)
Article
Immunology
Jinguo Suo, Yang Yang, Yuxin Che, Chunyan Chen, Xueying Lv, Xuelian Wang
Summary: It has been shown that a specific vaccine can inhibit the growth of pulmonary metastases from cervical cancer by inducing tumor-specific immune responses, increasing the attack on the tumor, and reducing the number of immunosuppressive cells. This suggests that therapeutic vaccines could be a promising treatment option for controlling metastatic tumors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Elham Beyranvand Nejad, Camilla Labrie, Tetje C. van der Sluis, Suzanne van Duikeren, Kees L. M. C. Franken, Rueshandra Roosenhoff, Ramon Arens, Thorbald van Hall, Sjoerd H. van der Burg
Summary: Elevated serum levels of IL-6 are associated with poor prognosis and chemotherapy resistance in various cancers, with unknown underlying mechanisms. This study demonstrated that tumor-produced IL-6 confers resistance to cisplatin and therapeutic vaccination, affecting the function of myeloid cells. However, combination therapies can overcome IL-6-mediated resistance, providing direction for more effective cancer treatments.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
G. de Jong, L. Bartels, M. Kedde, E. M. E. Verdegaal, M. A. Gillissen, S. E. Levie, M. G. Cercel, S. E. van Hal-van Veen, C. Fatmawati, D. van de Berg, E. Yasuda, Y. B. Claassen, A. Q. Bakker, S. H. van der Burg, R. Schotte, J. Villaudy, H. Spits, M. D. Hazenberg, P. M. van Helden, K. Wagner
Summary: Targeted cancer therapy using monoclonal antibodies has been successful for various types of cancer, but the availability of suitable antibody targets is limited. CD43s, a unique sialylated form of CD43 expressed by hematologic malignancies, has been identified as a potential therapeutic target against acute myeloid leukemia (AML) and myelodysplastic syndrome. The human antibody AT1413, derived from a high-risk AML patient, has been shown to interact with CD43s and may have therapeutic potential against various types of cancer, including melanoma and breast cancer.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Thomas C. van den Ende, Jeroen M. M. Heuts, Geoffroy P. P. Gential, Marten Visser, Michel J. van de Graaff, Nataschja Ho, Wim Jiskoot, A. Rob P. M. Valentijn, Nico J. Meeuwenoord, Herman S. Overkleeft, Jeroen D. C. Codee, Sjoerd H. van der Burg, Els M. E. Verdegaal, Gijsbert A. van der Marel, Ferry Ossendorp, Dmitri Filippov
Summary: Synthetic vaccines based on antigenic peptides expressed by tumors show promise for cancer immunotherapy, especially when adjuvanted with immunostimulatory additives. A novel conjugatable TLR2 ligand, mini-UPam, has been developed to improve solubility and physicochemical properties of synthetic peptides. The immunogenicity of mini-UPam-SP conjugates was demonstrated using T-cells from a cancer patient.
Article
Immunology
Tone Otterhaug, Sylvia Janetzki, Marij J. P. Welters, Monika Hakerud, Anne Grete Nedberg, Victoria Tudor Edwards, Sanne Boekestijn, Nikki M. Loof, Pal Kristian Selbo, Hans Olivecrona, Sjoerd H. van der Burg, Anders Hogset
Summary: PCI technology enhances immune responses by releasing endocytosed antigens via light-induced process. This study demonstrates that PCI vaccination combined with Hiltonol adjuvant is safe at low fimaporfin doses and shows promising immune responses in peptide and protein based vaccination.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Marit M. Melssen, Robin S. Lindsay, Katarzyna Stasiak, Anthony B. Rodriguez, Amanda M. Briegel, Salwador Cyranowski, Melanie R. Rutkowski, Mark R. Conaway, Cornelis J. M. Melief, Sjoerd H. van der Burg, Ukpong Eyo, Craig L. Slingluff, Victor H. Engelhard
Summary: The study found that the expression of integrins CD49a and CD49b on CD8(+) T cells in tumors changes over time, affecting T-cell infiltration and localization. CD49a expression in tumors may increase T cell motility and interfere with their recognition of tumor cells. This suggests a new mechanism by which the tumor microenvironment, and likely collagen, could impact the dysfunction of tumor-infiltrating CD8(+) T cells.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Elham Beyranvand Nejad, Camilla Labrie, Marit J. van Elsas, Jan Willem Kleinovink, Hans-Willi Mittrucker, Kees L. M. C. Franken, Sylvia Heink, Thomas Korn, Ramon Arens, Thorbald van Hall, Sjoerd H. van der Burg
Summary: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Koen A. Marijt, Lisa Griffioen, Laura Blijleven, Sjoerd. H. van der Burg, Thorbald van Hall
Summary: TEIPP is a novel category of cancer antigens that emerge on cancers with functional loss of peptide pump TAP, evoking CD8 T cell immune response. By studying LRPAP1(21-30)-specific CD8 T cells, it was found that replacing the serine anchor with valine in the signal sequence enhances HLA-A2 binding affinity and T cell stimulation.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Nadia de Gruil, Hanno Pijl, Sjoerd H. van der Burg, Judith R. Kroep
Summary: Stimulating our body's immune response through short-term fasting diets can enhance the efficacy of cancer therapy, particularly chemotherapy. This review summarizes the preclinical and clinical evidence supporting the synergistic effects of fasting diets with cancer therapy by boosting antitumor immunity. The potential mechanisms underlying these effects include enhanced tumor immunity, decreased growth signaling, and alleviation of immunosuppression. Further studies are needed to fully evaluate the benefits of combining short-term fasting with not only chemotherapy, but also immunotherapy in cancer treatment.
Article
Biochemistry & Molecular Biology
Marit J. van Elsas, Johan M. S. van der Schoot, Alexander Bartels, Kas Steuten, Duco van Dalen, Zacharias Wijfjes, Carl G. Figdor, Thorbald van Hall, Sjoerd H. van der Burg, Martijn Verdoes, Ferenc A. Scheeren
Summary: Regulatory T cells play a crucial role in immune suppression and pose challenges in cancer therapy. By optimizing the Fc domain of an antibody, efficient depletion of tumor-resident regulatory T cells can be achieved. Using a genome engineering strategy, a stable cell line producing optimized antibodies was generated, leading to effective depletion of tumor-resident regulatory T cells and enhanced tumor eradication when combined with other antibodies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Christianne Groeneveldt, Priscilla Kinderman, Jordi J. C. van Stigt Thans, Camilla Labrie, Lisa Griffioen, Marjolein Sluijter, Diana J. M. van den Wollenberg, Rob C. Hoeben, Joke M. M. den Haan, Sjoerd H. van Der Burg, Thorbald van Hall, Nadine van Montfoort
Summary: The study shows that primed reovirus-specific T cells can be used as potent effector cells for anticancer treatment. By designing a synthetic long peptide vaccination strategy, the intratumoral frequency of these specific T cells can be enhanced.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Shidi Wu, Marion Rietveld, Marieke Hogervorst, Frank de Gruijl, Sjoerd van der Burg, Maarten Vermeer, Remco van Doorn, Marij Welters, Abdoelwaheb El Ghalbzouri
Summary: The study demonstrated that papillary and reticular fibroblasts in the dermis have distinct effects on epithelial/non-epithelial tumors, particularly in promoting EMT and invasion processes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Jim Voorneveld, Max S. Kloet, Sven Wijngaarden, Robbert Q. . Kim, Angeliki Moutsiopoulou, Marnix Verdegaal, Mohit Misra, Ivan Dikic, Gijsbert A. . van der Marel, Herman S. Overkleeft, Dmitri V. Filippov, Gerbrand J. van der Heden van Noort
Summary: This article describes the development and optimization of a methodology for preparing peptides and proteins modified on the arginine residue with an ADPr group. The authors successfully obtained four regioisomers of ADP-ribosylated ubiquitin using this method and investigated the activity and selectivity of Legionella pneumophila ligase and hydrolase enzymes through biochemical experiments.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2022)
Article
Multidisciplinary Sciences
C. Stingl, S. P. Lau, S. H. van der Burg, J. G. Aerts, C. H. J. van Eijck, T. M. Luider
Summary: This study used proteomics analysis to investigate the potential of tumor-reactive T-cell response through vaccination of pancreatic cancer patients with an allogenic tumor cell lysate vaccine. The results identified 61 tumor antigens and quantified them using TMT labels.
Article
Oncology
Marit J. van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J. C. van Stigt Thans, Thorbald Van Hall, Sjoerd H. van der Burg
Summary: A small population of CD163(hi) tissue-resident macrophages is identified to be responsible for primary and secondary resistance against T-cell-based immunotherapies. While these CD163(hi) M2 macrophages are resistant to Csf1r-targeted therapies, in-depth characterization and identification of the underlying mechanisms driving immunotherapy resistance allows the specific targeting of this subset of macrophages, thereby creating new opportunities for therapeutic intervention with the aim to overcome immunotherapy resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J. M. Melief, Nina Bhardwaj
Summary: Therapeutic cancer vaccines aim to induce tumor regression, eradicate minimal residual disease, establish lasting anti-tumor memory, and avoid non-specific or adverse reactions. However, challenges arise due to tumor-induced immunosuppression and immunoresistance, hindering the achievement of these goals.
NATURE REVIEWS CANCER
(2021)